5 unknown, 3 completed, 1 active not recruiting, 1 recruiting. 9 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Unknown 4, Completed 3, Active not recruiting 1, Terminated 1 |
| Phase 1 | 7 | Completed 2, Unknown 2, Active not recruiting 1, Recruiting 1, Terminated 1 |
Follow Neoplasms, Experimental: new trials by email Literature Review of Neoplasms, Experimental trials Research Report on Neoplasms, Experimental
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL TBI-2001, Cyclophosphamide, Fludarabine - Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | University Health Network, Toronto | 19 | 2023-07-26 | 2026-06-09 |
| Phase 1 First-in-human Study of JS014 JS014, Interleukin 21 and humanized anti-human serum albumin VHH antibody, Pembrolizumab - anti-PD-1 antibody - Neoplasm Malignant, Neoplasm, Experimental | Phase 1 | Unknown | Anwita Biosciences | 60 | 2022-02-28 | 2023-09-06 |
| Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma Chidamide - Experimental Tumor | Phase 2 | Unknown | Peking University | 43 | 2018-09-01 | 2018-08-02 |
| Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients Chidamide, Cyclophosphamide, Doxorubicin - Experimental Tumor | Phase 2 | Unknown | Peking University | 114 | 2018-08-28 | 2018-09-04 |
| Chidamide for Patients With Recurrent and Metastatic Epstein-Barr Virus (EBV)-Associated Solid Tumors Chidamide - Experimental Tumor | Phase 2 | Unknown | Sun Yat-sen University | 66 | 2018-04-15 | 2018-04-11 |
| Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia TBI-1501 - Lymphoblastic Leukemia, Acute Adult | Phase 1 / Phase 2 | Active not recruiting | Takara Bio Inc. | 21 | 2017-06-01 | 2024-11-20 |
| Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes Cyclophosphamide or Bendamustine, Dose Level -1, Dose Level 1 - Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Unknown | Jichi Medical University | 18 | 2014-05-01 | 2014-11-06 |
| Sorafenib and TRC105 in Hepatocellular Cancer TRC 105, Sorafenib - Hepatoma, Liver Neoplasms | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 27 | 2011-02-11 | 2019-01-23 |
| Haploidentical NK Cell Infusion in Malignant Melanoma Haploidentical NK cell - Melanoma | Phase 1 / Phase 2 | Completed | Seoul National University Hospital | 12 | 2009-02-01 | 2012-06-08 |
| Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma DMF5 Melanoma Reactive TIL, Cyclophosphamide, Fludarabine - Melanoma, Malignant Melanoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 1 | 2007-08-01 | 2012-10-25 |
| Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma aldesleukin, therapeutic autologous lymphocytes, Cyclophosphamide - Melanoma, Malignant Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 158 | 2007-06-01 | 2013-06-03 |
Neoplasms (6) · Immune System Diseases (3) · Lymphoma (3) · Melanoma (3) · Melanoma, Experimental (3) · Neoplasms by Histologic Type (3) · Recurrence (2) · Adenoma, Liver Cell (1) · Burkitt Lymphoma (1) · Carcinoma, Hepatocellular (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Liver Neoplasms (1) · Liver Neoplasms, Experimental (1)
Neoplasms (5) · Neoplasms by Histologic Type (5) · Hemic and Lymphatic Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · Neoplasms by Site (4) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Nerve Tissue (3) · Neuroectodermal Tumors (3) · Neuroendocrine Tumors (3) · Nevi and Melanomas (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3)
Cyclophosphamide (5) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (3) · aldesleukin (2) · fludarabine (2) · fludarabine phosphate (2) · Bendamustine Hydrochloride (1) · Doxorubicin (1) · Etoposide (1) · Interleukin-2 (1) · Interleukin-21 (1) · Prednisone (1) · Sorafenib (1) · Vincristine (1) · Whole-Body Irradiation (1) · carotuximab (1)
National Cancer Institute (NCI) (3) · Peking University (2) · Anwita Biosciences (1) · Jichi Medical University (1) · Seoul National University Hospital (1) · Sun Yat-sen University (1) · Takara Bio Inc. (1) · University Health Network, Toronto (1)
China (3) · United States (3) · Japan (2) · Canada (1) · South Korea (1) · Taiwan (1)
Dae Seog Heo, Professor (1) · Deborah E Citrin, M.D. (1) · Keiya Ozawa, MD, PhD (1) · Marcus Butler, M.D. (1) · Steven Rosenberg, M.D. (1) · TJ Chiou, MD (1) · Tim F Greten, M.D. (1)